Therefore, pharmacological modification and genetic intervention targeted at COX‐2 activity seems to be a potential therapeutic strategy counteracting HBV infection and/or AFB1 exposure‐related hepatic steatosis, as well as hepatic diseases associated with necrotic cell death. The gene discussed is PTGS2; the disease is fatty liver disease.